Halozyme Therapeutics

Youtube Subscribe

Open: 33.03 Close: 32.98 Change: -0.05

The best way to get information about Halozyme Therapeutics Stock: Use an AI.

Are looking for the most relevant information about Halozyme Therapeutics? Investor spend a lot of time searching for information to make investment decisions in Halozyme Therapeutics. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Halozyme Therapeutics are: Halozyme, Therapeutics, earnings, share, price, measure, correlation, and the most common words in the summary are: therapeutic, halozyme, stock, inc, nasdaq, best, biotechnology, . One of the sentences in the summary was: CFO Nicole Labrosse sold 2,525 shares worth $124,381.50 on Thursday, February …

Concept Map

Semantic Network

Stock Summary

Halozyme Therapeutics, Inc. researches, develops, and commercializes proprietary enzymes and devices. Company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery.

Today's Summary

Arizona State Retirement System raised its holdings in shares of Halozyme. CFO Nicole Labrosse sold 2,525 shares worth $124,381.50 on Thursday, February 16th. Analysts expect Halozyme Therapeutics to post earnings of $0.44 per share for the quarter.

Today's News

Halozyme Therapeutics is scheduled to announce Q1 earnings results on Tuesday, May 9th, after market close. CFO Nicole Labrosse sold 2,525 shares worth $124,381.50 on Thursday, February 16th. Arizona State Retirement System raised its holdings in shares of Halozyme. Argus Research HALO: Raising target price to $36.00 HALOZYME THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $36.0000. There is a significant difference between Halozyme Therapeutics value and its price as these two measures arrived at by different measures arrived in different means. Investors typically determine if Halozyme is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition and analyst projections. The correlation of Halozyme Therapeutics is a statistical measure of how it moves in relation to other equities. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Halozyme. moves, either up or down, the other security will move in the same direction. Analysts expect Halozyme Therapeutics to post earnings of $0.44 per share for the quarter. The company has set its FY23 guidance at $2.50-2.65 EPS. Shares of the biopharma stock rose 1.9% after the company reaffirmed full-year earnings guidance. Halozyme Therapeutics has licensed its ENHANZE technology to leading pharmaceutical and biotechnology companies.

Stock Profile

"Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California."

Keywords

How much time have you spent trying to decide whether investing in Halozyme Therapeutics? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Halozyme Therapeutics are: Halozyme, Therapeutics, earnings, share, price, measure, correlation, and the most common words in the summary are: therapeutic, halozyme, stock, inc, nasdaq, best, biotechnology, . One of the sentences in the summary was: CFO Nicole Labrosse sold 2,525 shares worth $124,381.50 on Thursday, February 16th. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #therapeutic #halozyme #stock #inc #nasdaq #best #biotechnology.

Read more →

Youtube Subscribe

---